News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Merck & Co., Inc. (JOBS) Pulls Bid for EU Approval of Zolinza
February 17, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Feb 17 (Reuters) - Merck & Co has withdrawn its bid to get EU approval for its cutaneous T-cell lymphoma drug Zolinza, said the European regulator the EMEA.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Merck & Co.
MORE ON THIS TOPIC
Regulatory
FDA Breakthrough Designations Lead to Priority Reviews, Report Finds
November 20, 2025
·
1 min read
·
Dan Samorodnitsky
Lung cancer
Bayer Wins Lung Cancer Accelerated Approval for Kinase Inhibitor
November 20, 2025
·
1 min read
·
Tristan Manalac
FDA
Makary Eyes ‘America-First’ User Fee Structure as Renewal Negotiations Approach
November 19, 2025
·
2 min read
·
Tristan Manalac
Podcast
Billions More in M&A, Another Bidding War and More FDA Drama
November 19, 2025
·
1 min read
·
Heather McKenzie
